<DOC>
	<DOCNO>NCT02764333</DOCNO>
	<brief_summary>This Phase 2 clinical trial , test two investigational drug : TPIV200/huFR-1 ( also call TPIV200 ) , vaccine consist protein folate receptor alpha mixed GM-CSF , durvalumab ( MEDI4736 ) , antibody drug help un-block part immune system . The aim study find whether drug , give together safe , whether effective treat cancer .</brief_summary>
	<brief_title>TPIV200/huFR-1 ( A Multi-Epitope Anti-Folate Receptor Vaccine ) Plus Anti-PD-L1 MEDI4736 ( Durvalumab ) Patients With Platinum Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Folic Acid Antagonists</mesh_term>
	<criteria>Subjects must recurrent persistent platinumresistant epithelial ovarian , fallopian tube , primary peritoneal carcinoma measureable disease ( defined RECIST 1.1 . ) receive least one prior platinumbased therapy . Platinumbased therapy define treatment carboplatin , cisplatin another organoplatinum compound . Platinumresistant define disease progression within 6 month recent platinum therapy , disease progression receive previous platinumbased chemotherapy . Histologic documentation diagnosis carcinoma require follow histologic subtypes eligible : high grade serous , clear cell , endometrioid , carcinoma , adenocarcinoma , mixed ( include subtypes ) . Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Resolution ( nonlaboratory ) adverse effect recent surgery , radiotherapy , chemotherapy Grade ≤1 prior first study treatment ( exception alopecia neuropathy ; chemotherapyinduced peripheral neuropathy Grade ≤2 permit ) Patients must measurable disease . Measurable disease define RECIST ( version 1.1 ) . Measurable disease define least one lesion accurately measure least one dimension ( long diameter record ) previously irradiate . Each lesion must ≥ 10 mm measure CT , MRI caliper measurement clinical exam ; ≥ 20 mm measure chest xray . Lymph node must ≥ 15 mm short axis measure CT MRI . Adequate normal organ marrow function define follow laboratory result obtain within 14 day prior first treatment : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ( &gt; 1500 per mm3 ) Platelet ≥ 100 x 10^9/L ( &gt; 100,000 per mm3 ) Hemoglobin ≥ 9.0 g/dL Serum bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) . ( Unless Gilbert 's Syndrome , without concurrent clinically significant liver disease ) AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x institutional upper limit normal unless liver metastasis present , case must ≤ 5x ULN Serum creatinine CL &gt; 40 mL/min CockcroftGault formula ( Cockcroft Gault 1976 ) 24hour urine collection determination creatinine clearance : Creatinine CL = Weight ( kg ) x ( 140 Age ) x 0.85 ( mL/min ) 72 x serum creatinine ( mg/dL ) Female subject must either nonreproductive potential ( ie , postmenopausal history : ≥60 year old menses ≥1 year without alternative medical cause ; OR history hysterectomy , OR history bilateral tubal ligation , OR history bilateral oophorectomy ) must negative serum pregnancy test upon study entry . Subject willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) ; Previous enrollment present study . Participation another clinical study receipt investigational product last 4 week Any previous treatment PD1 PDL1 inhibitor , include durvalumab History another primary malignancy except : Malignancy treat curative intent know active disease ≥3 year first dose study drug low potential risk recurrence Adequately treat nonmelanoma skin cancer lentigo maligna without evidence disease Adequately treat carcinoma situ without evidence disease ( eg , cervical cancer situ ) Adequately treat stage 1 breast stage 1 low grade endometrial cancer Receipt last dose anticancer therapy ( chemotherapy , immunotherapy , endocrine therapy , target therapy , biologic therapy , tumor embolization , monoclonal antibody , investigational agent ) &lt; 21 day prior first dose study drug . Mean QT interval correct heart rate ( QTc ) &gt; /= 470 m calculate 3 electrocardiogram ( ECGs ) use Fridericia 's Correction Current prior use immunosuppressive medication within 28 day first dose durvalumab , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid . Steroid premedication CT scan contrast study drug , allowable , regardless dose . Any prior Grade &gt; /= 3 immunerelated adverse event ( irAE ) receive previous immunotherapy agent , unresolved irAE &gt; Grade 1 Active prior document autoimmune disease within past 2 year NOTE : Subjects vitiligo , Grave 's disease , psoriasis require systemic treatment ( within past 2 year ) exclude . Active prior document inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) History primary immunodeficiency History allogeneic organ transplant History hypersensitivity durvalumab excipient History hypersensitivity TPIV200 Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , active peptic ulcer disease gastritis , active bleeding diatheses include subject know evidence acute chronic hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) , psychiatric illness/social situation would limit compliance study requirement compromise ability subject give write informed consent Known history previous clinical diagnosis tuberculosis Receipt live attenuate vaccination within 30 day prior study entry within 30 day receive durvalumab Subjects pregnant , breastfeed reproductive potential employ effective method birth control Any condition , opinion investigator , would interfere evaluation study treatment interpretation patient safety study result Any condition , opinion investigator , would interfere evaluation study treatment interpretation patient safety study result Subjects uncontrolled seizure Known hypersensitivity reaction GMCSF adjuvant Patients develop evidence clinical radiologic pneumonitis , COP/BOOP , lung injury , treatment prior FRαtargeting therapy , mirvetuximab soravtansine ( IMGN853 ) , prior cancer immunotherapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TPIV200/huFR-1</keyword>
	<keyword>Anti-PD-L1</keyword>
	<keyword>vaccine</keyword>
	<keyword>16-011</keyword>
</DOC>